CORCEPT THERAPEUTICS INC (CORT) Stock Price & Overview
NASDAQ:CORT • US2183521028
The current stock price of CORT is 32.39 USD. Today CORT is down by -4%. In the past month the price decreased by -20.67%. In the past year, price decreased by -42.17%.
CORT Key Statistics
- Market Cap
- 3.445B
- P/E
- 39.50
- Fwd P/E
- 39.20
- EPS (TTM)
- 0.82
- Dividend Yield
- N/A
CORT Stock Performance
CORT Stock Chart
CORT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CORT. When comparing the yearly performance of all stocks, CORT is a bad performer in the overall market: 95.26% of all stocks are doing better.
CORT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CORT. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
CORT Earnings
On February 24, 2026 CORT reported an EPS of 0.2 and a revenue of 202.13M. The company missed EPS expectations (-34.64% surprise) and missed revenue expectations (-22.27% surprise).
CORT Forecast & Estimates
12 analysts have analysed CORT and the average price target is 85.68 USD. This implies a price increase of 164.53% is expected in the next year compared to the current price of 32.39.
For the next year, analysts expect an EPS growth of 0.76% and a revenue growth 19.16% for CORT
CORT Groups
Sector & Classification
CORT Financial Highlights
Over the last trailing twelve months CORT reported a non-GAAP Earnings per Share(EPS) of 0.82. The EPS decreased by -33.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.09% | ||
| ROA | 11.91% | ||
| ROE | 15.38% | ||
| Debt/Equity | 0 |
CORT Ownership
CORT Latest News, Press Relases and Analysis
CORT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.96 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.78 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.4 | 286.575B | ||
| PFE | PFIZER INC | 9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 120.05B | ||
| ZTS | ZOETIS INC | 16.31 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.88 | 26.461B | ||
| VTRS | VIATRIS INC | 5.5 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.56 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.91 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CORT
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
IPO: 2004-04-15
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025 US
CEO: Joseph K. Belanoff
Employees: 500
Phone: 16506888803
CORCEPT THERAPEUTICS INC / CORT FAQ
What does CORCEPT THERAPEUTICS INC do?
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Can you provide the latest stock price for CORCEPT THERAPEUTICS INC?
The current stock price of CORT is 32.39 USD. The price decreased by -4% in the last trading session.
What is the dividend status of CORCEPT THERAPEUTICS INC?
CORT does not pay a dividend.
What is the ChartMill rating of CORCEPT THERAPEUTICS INC stock?
CORT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the GICS sector and industry of CORT stock?
CORCEPT THERAPEUTICS INC (CORT) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in CORCEPT THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CORT.
Can you provide the upcoming earnings date for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) will report earnings on 2026-05-04.